Article citationsMore>>
T. Ogihara, T. Asano, K. Ando, Y. Chiba, H. Sakoda, M. Anai, N. Shojima, H. Ono, Y. Onishi, M. Fujishiro, H. Katagiri, Y. Fukushima, M. Kikuchi, N. Noguchi, H. Aburatani, I. Komuro and Y. Fujita, “Angiotensin II-Induced Insulin Resistance Is Associated with Enhanced Insulin Signaling,” Hypertension, Vol. 40, No. 6, 2002, pp. 872-879. doi:10.1161/01.HYP.0000040262.48405.A8
has been cited by the following article:
-
TITLE:
Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan
AUTHORS:
Yoichi Oikawa, Akira Shimada, Mizumi Kyo
KEYWORDS:
Albuminuria; Angiotensin II Receptor Blocker (ARB); Candesartan; Hypertension; Type 2 Diabetes
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.3 No.5,
September
20,
2013
ABSTRACT: Introduction: It was recently reported that candesartan, an
angiotensin II receptor blocker, had a protective effect against cardiovascular
events, comparable to that of calcium channel antagonists. Moreover, a
renoprotective effect and anti-diabetic action of candesartan had also been
demonstrated. However, whether the renoprotective effect of candesartan, especially
in diabetes, was dose-dependent or not remain to be fully elucidated. The
present study attempted to clarify the dose effect of renoprotection by
candesartan in Japanese type 2 diabetic patients. Subjects and Method: In this case series study, we recruited 26 type 2 diabetic patients with albuminuria whose
blood pressure did not reach the target BP level ( were increased
to the maximal dose in Japan, 12 mg/day. Clinical
parameters were examined before, at 6 and 12 months after the increase in dose. Results: An ameliorating effect of
the increased dose of candesartan on albuminuria and hypertension was
distinctly observed. No severe adverse effect was observed. Conclusion: It was highly possible that
the maximal dose of candesartan provided more effective renoprotection in
hypertensive type 2 diabetic patients initially treated with lower doses of
candesartan.